Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies

The Lancet

Volumn 385, Issue 9980, 2015, Pages 1835-1842

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; RECOMBINANT HORMONE;

ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; ENDOMETRIUM TUMOR; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LONG TERM CARE; META ANALYSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; RECALL BIAS; RISK FACTOR; SAMPLING BIAS; SENSITIVITY ANALYSIS; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG ADMINISTRATION; ESTROGEN THERAPY; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES; RISK ASSESSMENT; TRENDS; UTILIZATION;

DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 84929515264     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61687-1     Document Type: Article

References (17)

1. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. European Medicines Agency Guidelines on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003348.pdf (accessed Jan 1, 2014).
3. US Food and Drug Administration Estrogen and estrogen with progestin therapies for postmenopausal women www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm (accessed Jan 1, 2014).
4. Medicines and Healthcare products Regulatory Agency (MHRA) Hormone-replacement therapy: safety update. UK Public Assessment Report www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con2032228.pdf (accessed Jan 1, 2014).
5. V Beral, G Reeves, J Green, D Bull Ovarian cancer and hormone replacement therapy in the Million Women Study Lancet 369 2007 1703 1710
6. International Agency for Research on Cancer Monograph Volume 91: combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy 2007 International Agency for Research on Cancer Lyon, France
7. TJ de Villiers, A Pines, N Panay et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health Climacteric 16 2013 316 337
8. LS Mørch, E Løkkegaard, AH Andreasen et al. Hormone therapy and ovarian cancer JAMA 302 2009 289 305
9. Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies Lancet Oncology 13 2012 1141 1151
10. AG Fritz, C Percy, A Jack et al. International classification of diseases for oncology (ICD-O) 2000 World Health Organization Geneva
11. M Plummer Improved estimates of floating absolute risk Stat Med 23 2004 93 104
12. Office for National Statistics National Cancer Statistics for England http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Cancer (accessed Jan 1, 2014).
13. C Rodriguez, AV Patel, EE Calle, EJ Jacob, MJ Thun Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women JAMA 285 2001 1460 1465
14. Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies Lancet Oncol 13 2012 946 956
15. Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and body size: individual participant meta-analysis including 25 157 women with ovarian cancer from 47 epidemiological studies PloS Med 9 2012 e1001200 10.1371/journal.pmed.1001200
16. RJ Kurman, IeM Shih Molecular pathogenesis and extra-ovarian origin of epithelial ovarian cancer - shifting the paradigm Hum Pathol 42 2011 918 931
17. Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls Lancet 371 2008 303 314